key: cord-1036448-ilkgxxfo authors: Sharma, Surendra; Burd, Irina; Liao, Aihua title: Special Issue on COVID‐19 and Pregnancy: Consequences for Maternal and Neonatal Health date: 2020-10-01 journal: Am J Reprod Immunol DOI: 10.1111/aji.13354 sha: 8ebcccf642ae440752dd63c282a588c48fb0ac7f doc_id: 1036448 cord_uid: ilkgxxfo Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) quickly spread worldwide as a once in a century pandemic in the form of a Coronavirus Disease 2019 (COVID‐19). COVID‐19 has taken only a few months since it was declared pandemic by the World Health Organization in March, 2020 to affect close to 29 million vulnerable people and inflict approximately 1 million deaths across continents. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly spread worldwide as a once in a century pandemic in the form of a Coronavirus Disease 2019 (COVID-19). COVID-19 has taken only a few months since it was declared pandemic by the World Health Organization in March, 2020 to affect close to 29 million vulnerable people and inflict approximately 1 million deaths across continents. 1 Initial cases of COVID-19 disease patients were first identified in Wuhan, China in December, 2019 and January, 2020. One major factor that has baffled clinicians and scientists is that this pandemic has spread in a sustained manner without significant reduction in transmissibility. Among the vulnerable populations, pregnant women and their fetuses have traditionally represented a high-risk population during viral pandemics; however, this pandemic demonstrated altered maternal immunity 2, 3 and effect on gametogenesis 4 and organogenesis 5 as well as placental function. 6, 7 To date, outcomes of several cohorts of pregnant women have been reported, with no definite evidence of mortality and vertical transmission. 8, 9, 10 On the other hand, there are reports of preterm deliveries, albeit at a suggested higher rate compared to non-COVID pregnant women, and stillbirth. 9 (Figure 1) . We hope this issue will be of benefit to researchers globally, interested in the role of COVID-19 in pregnancy complications. This article is protected by copyright. All rights reserved Just in the last few months, there has been an explosion of publications on COVID-19 in general, including those reporting on clinical consequences for pregnant women. However, the information to the general public has suffered from fragmented reports and data derived from small cohorts and even individual cases. In this Special Issue we have compiled a collection of twelve manuscripts that cover most of the important issues relating to COVID-19 and pregnancy. The manuscripts cover themes on immunology, placenta, receptor biology, risk factors to infection progression and most importantly clinical consequences. [2] [3] [4] [5] [6] [7] [8] [11] [12] [13] [14] Each review is authored by experts on the specific topic of their respective research and/or clinical work. SARS-CoV-2 belongs to the family of the severe acute respiratory syndrome coronaviruses (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and exploits the same ACE2-TMPRSS2 receptor complex as the other coronaviruses. 15 There are some unique observations of COVID-19 disease in pregnant women. Unlike other coronaviruses, SARS-CoV-2 infected individuals remain asymptomatic for 5-7 days. In most cases, pregnant women remain asymptomatic with rare incidence of mortality. In COVID-19 disease patients, lymphopenia has been correlated with mortality. This poses a question whether pregnancy presents itself as an immunological contributor to severe or controlled COVID-19 disease. No definite evidence of vertical transmission has been presented. This places the placenta at the center of the question of vertical transmission. There have been reports of temporal expression of ACE2 in the placenta, suggesting that gestational agedependent ACE2 expression may curtail or enhance vertical transmission. 16, 17 Several manuscripts have been included to provide up to date information on all these relevant questions. Several manuscripts have been devoted to review the current data and conceptualize the various factors integral to the understanding of diagnostic challenges, therapeutic controversies, intrauterine transmission, and maternal and neonatal complications. These reviews cover the entire gestation period from disease severity, management considerations for care of severe and critically ill women, overall clinical manifestations of COVID-19 disease, role of co-infections, and prenatal care and labor. WHO Coronavirus Disease (COVID-19) Dashboard Abbas AM COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical Transmission SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2 This article is protected by copyright. All rights reserved It is important to note that a few manuscripts discuss a country-centric COVID-19 disease in pregnant women and clinical care in respective countries. 8, 18 We believe that manuscripts included in this special issue will provide cutting edge insights for COVID-19 disease in pregnant women and its effects on maternal and neonatal health. This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia. Am J Obstet Gynecol. 2020; S0002-9378(20)30884-X.18. Sharma JB, Sharma E, Sharma S, Singh S.